tetano
Editor, Senior Moderator
J Eur Acad Dermatol Venereol
. 2021 Mar 16.
doi: 10.1111/jdv.17225. Online ahead of print.
Prompt onset of erythema multiforme following the first BNT162b2 SARS-CoV-2 vaccination
T Gambichler[SUP] 1 [/SUP], L Scholl[SUP] 1 [/SUP], L Ocker[SUP] 1 [/SUP], R Stranzenbach[SUP] 1 [/SUP]
Affiliations
Abstract
In December 2020, the SARS-CoV-2 vaccine (BNT162b2, Comirnaty?, BioNTech/Pfizer) was approved by the European Medicines Agency. Recently, BNT162b2 was started to be administered to high-risk populations for COVID-19 in Germany.[SUP]1[/SUP] We here report the first case of an elderly patient who developed erythema multiforme after the first day of vaccination with BNT162b2.
Keywords: COVID-19; SARS-CoV-2; comirnaty; coronavirus; erythema multiforme; vaccination; vaccine.
. 2021 Mar 16.
doi: 10.1111/jdv.17225. Online ahead of print.
Prompt onset of erythema multiforme following the first BNT162b2 SARS-CoV-2 vaccination
T Gambichler[SUP] 1 [/SUP], L Scholl[SUP] 1 [/SUP], L Ocker[SUP] 1 [/SUP], R Stranzenbach[SUP] 1 [/SUP]
Affiliations
- PMID: 33725406
- DOI: 10.1111/jdv.17225
Abstract
In December 2020, the SARS-CoV-2 vaccine (BNT162b2, Comirnaty?, BioNTech/Pfizer) was approved by the European Medicines Agency. Recently, BNT162b2 was started to be administered to high-risk populations for COVID-19 in Germany.[SUP]1[/SUP] We here report the first case of an elderly patient who developed erythema multiforme after the first day of vaccination with BNT162b2.
Keywords: COVID-19; SARS-CoV-2; comirnaty; coronavirus; erythema multiforme; vaccination; vaccine.